Literature DB >> 19488077

Update on strategies to increase HDL quantity and function.

Danielle Duffy1, Daniel J Rader.   

Abstract

Low levels of HDL cholesterol are a significant predictor of atherosclerotic cardiovascular events. HDL is believed to protect against atherosclerosis by promoting reverse cholesterol transport, and potentially through anti-inflammatory, antioxidative, antithrombotic and nitric oxide effects. The multiple mechanisms of action, as well as a limited ability to measure these properties, make HDL a complex therapeutic target, albeit one with immense potential for the treatment of patients with atherosclerosis. Here, we discuss new therapeutic strategies currently being developed, which have the potential to increase plasma levels of HDL cholesterol and/or improve HDL function.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19488077     DOI: 10.1038/nrcardio.2009.94

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN: 1759-5002            Impact factor:   32.419


  86 in total

1.  Niacin mediates lipolysis in adipose tissue through its G-protein coupled receptor HM74A.

Authors:  Youyan Zhang; Robert J Schmidt; Patricia Foxworthy; Renee Emkey; Jennifer K Oler; Thomas H Large; He Wang; Eric W Su; Marion K Mosior; Patrick I Eacho; Guoqing Cao
Journal:  Biochem Biophys Res Commun       Date:  2005-08-26       Impact factor: 3.575

2.  Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation.

Authors:  A Inazu; M L Brown; C B Hesler; L B Agellon; J Koizumi; K Takata; Y Maruhama; H Mabuchi; A R Tall
Journal:  N Engl J Med       Date:  1990-11-01       Impact factor: 91.245

3.  Acute effects of intravenous infusion of ApoA1/phosphatidylcholine discs on plasma lipoproteins in humans.

Authors:  M N Nanjee; J E Doran; P G Lerch; N E Miller
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-04       Impact factor: 8.311

4.  Effect of torcetrapib on the progression of coronary atherosclerosis.

Authors:  Steven E Nissen; Jean-Claude Tardif; Stephen J Nicholls; James H Revkin; Charles L Shear; William T Duggan; Witold Ruzyllo; William B Bachinsky; Gabriel P Lasala; Gregory P Lasala; E Murat Tuzcu
Journal:  N Engl J Med       Date:  2007-03-26       Impact factor: 91.245

5.  Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers.

Authors:  J J Repa; S D Turley; J A Lobaccaro; J Medina; L Li; K Lustig; B Shan; R A Heyman; J M Dietschy; D J Mangelsdorf
Journal:  Science       Date:  2000-09-01       Impact factor: 47.728

6.  HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway.

Authors:  Fumihiko Matsuura; Nan Wang; Wengen Chen; Xian-Cheng Jiang; Alan R Tall
Journal:  J Clin Invest       Date:  2006-05       Impact factor: 14.808

7.  Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice.

Authors:  B Föger; M Chase; M J Amar; B L Vaisman; R D Shamburek; B Paigen; J Fruchart-Najib; J A Paiz; C A Koch; R F Hoyt; H B Brewer; S Santamarina-Fojo
Journal:  J Biol Chem       Date:  1999-12-24       Impact factor: 5.157

8.  Molecular identification of nicotinic acid receptor.

Authors:  Takatoshi Soga; Masazumi Kamohara; Jun Takasaki; Shun-ichiro Matsumoto; Tetsu Saito; Takahide Ohishi; Hideki Hiyama; Ayako Matsuo; Hitoshi Matsushime; Kiyoshi Furuichi
Journal:  Biochem Biophys Res Commun       Date:  2003-03-28       Impact factor: 3.575

9.  Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice.

Authors:  José W A van der Hoorn; Willeke de Haan; Jimmy F P Berbée; Louis M Havekes; J Wouter Jukema; Patrick C N Rensen; Hans M G Princen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-07-31       Impact factor: 8.311

10.  Discovery of potent, selective sulfonylfuran urea endothelial lipase inhibitors.

Authors:  Krista B Goodman; Michael J Bury; Mui Cheung; Maria A Cichy-Knight; Sarah E Dowdell; Allison K Dunn; Dennis Lee; Jeffrey A Lieby; Michael L Moore; Daryl A Scherzer; Deyou Sha; Dominic P Suarez; Dennis J Murphy; Mark R Harpel; Eric S Manas; Dean E McNulty; Roland S Annan; Rosalie E Matico; Benjamin K Schwartz; John J Trill; Thomas D Sweitzer; Da-Yuan Wang; Paul M Keller; John A Krawiec; Michael C Jaye
Journal:  Bioorg Med Chem Lett       Date:  2008-11-14       Impact factor: 2.823

View more
  69 in total

1.  Nascent HDL formation by hepatocytes is reduced by the concerted action of serum amyloid A and endothelial lipase.

Authors:  Joanne M Wroblewski; Anisa Jahangiri; Ailing Ji; Frederick C de Beer; Deneys R van der Westhuyzen; Nancy R Webb
Journal:  J Lipid Res       Date:  2011-09-27       Impact factor: 5.922

2.  4F Peptide reduces nascent atherosclerosis and induces natural antibody production in apolipoprotein E-null mice.

Authors:  Geoffrey D Wool; Veneracion G Cabana; John Lukens; Peter X Shaw; Christoph J Binder; Joseph L Witztum; Catherine A Reardon; Godfrey S Getz
Journal:  FASEB J       Date:  2010-09-27       Impact factor: 5.191

Review 3.  The protein cargo of HDL: implications for vascular wall biology and therapeutics.

Authors:  Jay W Heinecke
Journal:  J Clin Lipidol       Date:  2010 Sep-Oct       Impact factor: 4.766

Review 4.  How do elevated triglycerides and low HDL-cholesterol affect inflammation and atherothrombosis?

Authors:  Francine K Welty
Journal:  Curr Cardiol Rep       Date:  2013-09       Impact factor: 2.931

5.  Uremia alters HDL composition and function.

Authors:  Michael Holzer; Ruth Birner-Gruenberger; Tatjana Stojakovic; Dalia El-Gamal; Veronika Binder; Christian Wadsack; Akos Heinemann; Gunther Marsche
Journal:  J Am Soc Nephrol       Date:  2011-07-29       Impact factor: 10.121

6.  Inhibition of ABCA1 protein degradation promotes HDL cholesterol efflux capacity and RCT and reduces atherosclerosis in mice.

Authors:  LinZhang Huang; BaoYan Fan; Ang Ma; Philip W Shaul; HaiBo Zhu
Journal:  J Lipid Res       Date:  2015-03-11       Impact factor: 5.922

Review 7.  Common Pathogenesis of Acne Vulgaris and Atherosclerosis.

Authors:  Hao Jiang; Changyi Li
Journal:  Inflammation       Date:  2019-02       Impact factor: 4.092

8.  Site-specific 5-hydroxytryptophan incorporation into apolipoprotein A-I impairs cholesterol efflux activity and high-density lipoprotein biogenesis.

Authors:  Maryam Zamanian-Daryoush; Valentin Gogonea; Anthony J DiDonato; Jennifer A Buffa; Ibrahim Choucair; Bruce S Levison; Randall A Hughes; Andrew D Ellington; Ying Huang; Xinmin S Li; Joseph A DiDonato; Stanley L Hazen
Journal:  J Biol Chem       Date:  2020-02-25       Impact factor: 5.157

9.  Effect of bariatric surgery on microvascular dysfunction associated to metabolic syndrome: a 12-month prospective study.

Authors:  J F Martín-Rodríguez; A Cervera-Barajas; A Madrazo-Atutxa; P P García-Luna; J L Pereira; J Castro-Luque; A León-Justel; S Morales-Conde; J R Castillo; A Leal-Cerro; D A Cano
Journal:  Int J Obes (Lond)       Date:  2014-01-28       Impact factor: 5.095

10.  Pegylation of high-density lipoprotein decreases plasma clearance and enhances antiatherogenic activity.

Authors:  Alan R Tall; Nan Wang; Andrew J Murphy; Samuel Funt; Darren Gorman
Journal:  Circ Res       Date:  2013-04-23       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.